Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted Change in Account Payables of -$204000.0 for Q2 2026, down 137.16% on a QoQ basis from $549000.0 in Q1 2026, and down 173.38% year-over-year from $278000.0 in Q2 2025.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Change in Account Payables for 7 years, with the latest figure at -$204000.0 in Q2 2026.
- On a quarterly basis, Change in Account Payables fell 173.38% year-over-year to -$204000.0 in Q2 2026; TTM through Jun 2026 was -$1.1 million, a 188.54% decrease from a year earlier, with the FY2025 full-year figure at -$1.0 million, down 247.68% from the prior year.
- Change in Account Payables was -$204000.0 for Q2 2026 at Rani Therapeutics Holdings, down from $549000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.1 million in Q3 2024, with the low at -$2.2 million in Q4 2025.
- Average Change in Account Payables over 5 years is -$23666.7, with a median of $104500.0 recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables jumped 362.5% in 2022, then sank 942.51% in 2025.
- Over 5 years, Change in Account Payables stood at -$214000.0 in 2022, then sank by 209.81% to -$663000.0 in 2023, then surged by 68.78% to -$207000.0 in 2024, then tumbled by 942.51% to -$2.2 million in 2025, then jumped by 90.55% to -$204000.0 in 2026.
- The last three Change in Account Payables figures came in at -$204000.0 (Q2 2026), $549000.0 (Q1 2026), and -$2.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | -204,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -204,000.00 |
| Mar 31, 2026 | 549,000.00 |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | 669,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | -207,000.00 |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | -300,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Dec 31, 2023 | -663,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | -408,000.00 |
| Mar 31, 2023 | 76,000.00 |
| Dec 31, 2022 | -214,000.00 |
| Sep 30, 2022 | 168,000.00 |
| Jun 30, 2022 | 131,000.00 |
| Mar 31, 2022 | 78,000.00 |
| Dec 31, 2021 | -131,000.00 |
| Sep 30, 2021 | -64,000.00 |